Cargando…

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma

SIMPLE SUMMARY: Pegfilgrastim, the pegylated form of filgrastim (recombinant human GCSF) is widely adopted as supportive care for preventing neutropenia or febrile neutropenia episodes during chemotherapy. Neutropenia is directly cause of potentially severe infections and indirectly cause of treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerchione, Claudio, Nappi, Davide, Romano, Alessandra, Martinelli, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455015/ https://www.ncbi.nlm.nih.gov/pubmed/36077600 http://dx.doi.org/10.3390/cancers14174063

Ejemplares similares

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report
por: Cerchione, Claudio, et al.
Publicado: (2020)

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
por: Cerchione, Claudio, et al.
Publicado: (2016)

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
por: Cerchione, Claudio, et al.
Publicado: (2016)

P042: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2022)

Hodgkin lymphoma: flow me?
por: Beaty, Michael W, et al.
Publicado: (2005)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

Epstein Barr Virus-Associated Hodgkin Lymphoma
por: Carbone, Antonino, et al.
Publicado: (2018)

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
por: Cornes, Paul, et al.
Publicado: (2020)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma
por: Hatayama, Mayumi, et al.
Publicado: (2018)

Late relapses in Hodgkin lymphoma – should we search for the needle in the haystack?
por: El‐Galaly, Tarec Christoffer, et al.
Publicado: (2022)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

P1288: ALTERED AMINO ACID HOMEOSTASIS CAN ELICIT AN ADAPTIVE RESPONSE VIA UPREGULATION OF UFMYLATION IN HODGKIN LYMPHOMA
por: Romano, A., et al.
Publicado: (2022)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Commentary on Methodologic choices in synthesizing epidemiologic evidence to assess perchloroethylene and non-Hodgkin's lymphoma
por: Savitz, David A.
Publicado: (2022)

Pathobiology of Hodgkin Lymphoma
por: Agostinelli, Claudio, et al.
Publicado: (2014)

Survival from non-Hodgkin lymphoma in England and Wales up to 2001
por: Johnson, P W M
Publicado: (2008)

Advanced stage Hodgkin Lymphoma: patient management
por: Gini, Guido, et al.
Publicado: (2020)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies
por: Civoli, Francesca, et al.
Publicado: (2022)

Commentary: Quantifying the impact of bias to inform quality assessments in systematic reviews: The case of perchloroethylene and Non-Hodgkin's lymphoma
por: Fox, Matthew P., et al.
Publicado: (2022)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Pathobiology of Hodgkin Lymphoma
por: Piccaluga, Pier Paolo, et al.
Publicado: (2011)

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis
por: Cerchione, Claudio, et al.
Publicado: (2017)

How I Manage Chronic Lymphocytic Leukemia
por: Nasnas, Patrice, et al.
Publicado: (2023)

Relapsing Acute Kidney Injury Associated with Pegfilgrastim
por: Arora, Swati, et al.
Publicado: (2012)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

Exposure to glyphosate and risk of non-hodgkin lymphoma: an updated meta-analysis
por: Boffetta, Paolo, et al.
Publicado: (2021)

Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy
por: Wang, Xiao Jun, et al.
Publicado: (2016)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
por: Romano, Alessandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7htobq748qr9kgr4okgoea998l